Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 10
Submit an article Journal homepage
631
Views
107
CrossRef citations to date
0
Altmetric
Review

Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment

Johann DD Pitout Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada and Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada and Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada. [email protected]; Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada and Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada and Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada. [email protected]
Pages 1165-1176 | Published online: 10 Jan 2014

References

  • Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2(2), 123–140 (2004).
  • Herzer PJ, Inouye S, Inouye M, Whittam TS. Phylogenetic distribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of Escherichia coli. J. Bacteriol. 172(11), 6175–6181 (1990).
  • Mokady D, Gophna U, Ron EZ. Virulence factors of septicemic Escherichia coli strains. Int. J. Med. Microbiol. 295(6–7), 455–462 (2005).
  • Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp. Mol. Pathol. 85(1), 11–19 (2008).
  • Foxman B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 7(12), 653–660 (2010).
  • Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14(9), 413–420 (2006).
  • Jacoby GA, Munoz-Price LS. The new beta-lactamases. N. Engl. J. Med. 352(4), 380–391 (2005).
  • Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infect. Dis. 17(10), 1791–1798 (2011).
  • Sullivan CB, Diggle MA, Clarke SC. Multilocus sequence typing: data analysis in clinical microbiology and public health. Mol. Biotechnol. 29(3), 245–254 (2005).
  • Mushtaq S, Irfan S, Sarma JB et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J. Antimicrob. Chemother. 66(9), 2002–2005 (2011).
  • Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD. New Delhi metallo-beta-lactamase from traveler returning to Canada. Emerging Infect. Dis. 17(2), 242–244 (2011).
  • Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum b-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J. Clin. Microbiol. 50(2), 294–299 (2012).
  • Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657–686 (2005).
  • Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol. 9(5), 466–475 (2006).
  • Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8(3), 159–166 (2008).
  • Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 35(4), 316–321 (2010).
  • Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob. Agents Chemother. 53(7), 2846–2851 (2009).
  • Johnson JR, Nicolas-Chanoine MH, DebRoy C et al. MASTER Investigators. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967–2009. Emerging Infect. Dis. 18(4), 598–607 (2012).
  • Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob. Agents Chemother. 53(7), 2733–2739 (2009).
  • Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51(3), 286–294 (2010).
  • Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J. Antimicrob. Chemother. 63(1), 72–79 (2009).
  • van der Bij AK, Peirano G, Goessens WH, van der Vorm ER, van Westreenen M, Pitout JD. Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob. Agents Chemother. 55(7), 3576–3578 (2011).
  • Kim J, Bae IK, Jeong SH, Chang CL, Lee CH, Lee K. Characterization of IncF plasmids carrying the blaCTX-M-14 gene in clinical isolates of Escherichia coli from Korea. J. Antimicrob. Chemother. 66(6), 1263–1268 (2011).
  • Mshana SE, Imirzalioglu C, Hain T, Domann E, Lyamuya EF, Chakraborty T. Multiple ST clonal complexes, with a predominance of ST131, of Escherichia coli harbouring blaCTX-M-15 in a tertiary hospital in Tanzania. Clin. Microbiol. Infect. 17(8), 1279–1282 (2011).
  • Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerging Infect. Dis. 14(2), 195–200 (2008).
  • Jones GL, Warren RE, Skidmore SJ, Davies VA, Gibreel T, Upton M. Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 62(6), 1245–1251 (2008).
  • Mihaila L, Wyplosz B, Clermont O et al. Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone. J. Antimicrob. Chemother. 65(7), 1537–1539 (2010).
  • Smet A, Martel A, Persoons D et al. Characterization of extended-spectrum beta-lactamases produced by Escherichia coli isolated from hospitalized and nonhospitalized patients: emergence of CTX-M-15-producing strains causing urinary tract infections. Microb. Drug Resist. 16(2), 129–134 (2010).
  • Cortés P, Blanc V, Mora A et al. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl. Environ. Microbiol. 76(9), 2799–2805 (2010).
  • Zong Z, Yu R. Escherichia coli carrying the blaCTX-M-15 gene of ST648. J. Med. Microbiol. 59(Pt 12), 1536–1537 (2010).
  • Van der Bij AK, Peirano G, Pitondo-Silva A, Pitout JD. The presence of genes encoding for different virulence factors in clonally related Escherichia coli that produce CTX-Ms. Diagn. Microbiol. Infect. Dis. 72(4), 297–302 (2012).
  • Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42(5), 657–668 (2006).
  • Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob. Agents Chemother. 46(1), 1–11 (2002).
  • Doi Y, Paterson DL. Detection of plasmid-mediated class C beta-lactamases. Int. J. Infect. Dis. 11(3), 191–197 (2007).
  • Ding H, Yang Y, Lu Q et al. The prevalence of plasmid-mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children’s hospitals in China. Eur. J. Clin. Microbiol. Infect. Dis. 27(10), 915–921 (2008).
  • Li Y, Li Q, Du Y et al. Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. J. Clin. Microbiol. 46(4), 1317–1321 (2008).
  • Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS. Prevalence of newer beta-lactamases in Gram-negative clinical isolates collected in the United States from 2001 to 2002. J. Clin. Microbiol. 44(9), 3318–3324 (2006).
  • Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int. J. Antimicrob. Agents 28(6), 578–581 (2006).
  • Woodford N, Reddy S, Fagan EJ et al. Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland. J. Antimicrob. Chemother. 59(1), 102–105 (2007).
  • Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob. Agents Chemother. 48(2), 533–537 (2004).
  • Mulvey MR, Bryce E, Boyd DA et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob. Agents Chemother. 49(1), 358–365 (2005).
  • Pai H, Kang CI, Byeon JH et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(10), 3720–3728 (2004).
  • Pitout JD, Gregson DB, Church DL, Laupland KB. Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerging Infect. Dis. 13(3), 443–448 (2007).
  • Varma JK, Marcus R, Stenzel SA et al. Highly resistant Salmonella Newport-MDRAmpC transmitted through the domestic US food supply: a FoodNet case–control study of sporadic Salmonella Newport infections, 2002–2003. J. Infect. Dis. 194(2), 222–230 (2006).
  • Pitout JD, Reisbig MD, Mulvey M et al. Association between handling of pet treats and infection with Salmonella enterica serotype newport expressing the AmpC beta-lactamase, CMY-2. J. Clin. Microbiol. 41(10), 4578–4582 (2003).
  • Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob. Agents Chemother. 52(10), 3814–3816 (2008).
  • Qin X, Zerr DM, Weissman SJ et al. Prevalence and mechanisms of broad-spectrum beta-lactam resistance in Enterobacteriaceae: a children’s hospital experience. Antimicrob. Agents Chemother. 52(11), 3909–3914 (2008).
  • Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 20(3), 440–458 (2007).
  • Walther-Rasmussen J, Høiby N. Class A carbapenemases. J. Antimicrob. Chemother. 60(3), 470–482 (2007).
  • Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn. Microbiol. Infect. Dis. 56(4), 367–372 (2006).
  • Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9(4), 228–236 (2009).
  • Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the beta-lactamase blaKPC gene. Antimicrob. Agents Chemother. 52(4), 1257–1263 (2008).
  • Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2(5), 501–512 (2007).
  • Cornaglia G, Akova M, Amicosante G et al.; ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS). Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int. J. Antimicrob. Agents 29(4), 380–388 (2007).
  • Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046–5054 (2009).
  • Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597–602 (2010).
  • Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob. Agents Chemother. 55(3), 1274–1278 (2011).
  • Castanheira M, Mendes RE, Woosley LN, Jones RN. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007–09). J. Antimicrob. Chemother. 66(6), 1409–1411 (2011).
  • Lascols C, Hackel M, Marshall SH et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J. Antimicrob. Chemother. 66(9), 1992–1997 (2011).
  • Seema K, Ranjan Sen M, Upadhyay S, Bhattacharjee A. Dissemination of the New Delhi metallo-b-lactamase-1 (NDM-1) among Enterobacteriaceae in a tertiary referral hospital in north India. J. Antimicrob. Chemother. 66(7), 1646–1647 (2011).
  • Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised. J. Assoc. Physicians India 58, 147–149 (2010).
  • Perry JD, Naqvi SH, Mirza IA et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J. Antimicrob. Chemother. 66(10), 2288–2294 (2011).
  • Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. 19(12), 588–595 (2011).
  • Leverstein-Van Hall MA, Stuart JC, Voets GM, Versteeg D, Tersmette T, Fluit AC. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis. 10(12), 830–831 (2010).
  • Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11(5), 355–362 (2011).
  • Peirano G, Schreckenberger PC, Pitout JD. Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrob. Agents Chemother. 55(6), 2986–2988 (2011).
  • Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(1), 15–22 (2004).
  • Carrër A, Poirel L, Yilmaz M et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob. Agents Chemother. 54(3), 1369–1373 (2010).
  • Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P. Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob. Agents Chemother. 52(9), 3463–3464 (2008).
  • Glupczynski Y, Huang TD, Bouchahrouf W et al. Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. Int. J. Antimicrob. Agents 39(2), 168–172 (2012).
  • Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob. Agents Chemother. 56(1), 559–562 (2012).
  • Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Wayne, PA, USA (2009).
  • Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Wayne, PA, USA (2012).
  • Naas T, Cuzon G, Truong H, Bernabeu S, Nordmann P. Evaluation of a DNA microarray, the check-points ESBL/KPC array, for rapid detection of TEM, SHV, and CTX-M extended-spectrum beta-lactamases and KPC carbapenemases. Antimicrob. Agents Chemother. 54(8), 3086–3092 (2010).
  • Pitout JD, Le PG, Moore KL, Church DL, Gregson DB. Detection of AmpC beta-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory. Clin. Microbiol. Infect. 16(2), 165–170 (2010).
  • Brolund A, Wisell KT, Edquist PJ, Elfström L, Walder M, Giske CG. Development of a real-time SYBRGreen PCR assay for rapid detection of acquired AmpC in Enterobacteriaceae. J. Microbiol. Methods 82(3), 229–233 (2010).
  • Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40(6), 2153–2162 (2002).
  • Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V; European Network on Carbapenemases. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect. 18(5), 432–438 (2012).
  • Girlich D, Poirel L, Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J. Clin. Microbiol. 50(2), 477–479 (2012).
  • Naas T, Cuzon G, Bogaerts P,Glupczynski Y, Nordmann P. Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum β-lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases. J. Clin. Microbiol. 49(4), 1608–1613 (2011).
  • Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41(6), 848–854 (2005).
  • Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32(8), 1162–1171 (2001).
  • Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51(6), 1987–1994 (2007).
  • Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70(3), 313–333 (2010).
  • Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev. Anti. Infect. Ther. 6(5), 671–683 (2008).
  • Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J. Infect. 57(6), 441–448 (2008).
  • Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P. Addressing the challenge of extended-spectrum beta-lactamases. Curr. Opin. Investig. Drugs 10(2), 172–180 (2009).
  • Titelman E, Iversen A, Kahlmeter G, Giske CG. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 119(12), 853–863 (2011).
  • Titelman E, Iversen A, Kalin M, Giske CG. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb. Drug Resist. 18(2), 189–192 (2012).
  • Lampri N, Galani I, Poulakou G et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J. Antimicrob. Chemother. (2012).
  • Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs 72(1), 1–16 (2012).
  • Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents 36(Suppl. 2), S50–S54 (2010).
  • Stone NR, Woodford N, Livermore DM et al. Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. J. Antimicrob. Chemother. 66(11), 2677–2678 (2011).
  • Pitout JD. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Front. Microbiol. 3, 9 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.